On June 12, 2024, Filament Health Corp. closed the transaction. The common shares issued to Negev and Lightburn pursuant to the financing are subject to a four-month-and-one-day hold period in accordance with applicable securities laws.

As a result of the exercise of warrants and the conversion of the note, Negev has become a holder of greater than 20% of the issued and outstanding common shares. The transaction included participation from returning investor Negev Capital Fund One L.P. Fund managed by Negev Capital for 17,284,443 common shares for approximately CAD 900,000.